CTRI/2022/11/047219已完成2 期
Clinical Evaluation of Efficacy and Safety of Keranyaa in improving hair health including hair volume, hair softness, hair strength in healthy adult volunteers
Transformative Learning Solutions Pvt Ltd0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Female and Male subjects in general good health.
- •2.Subjects in the age group 18-55 years (both the ages inclusive).
- •3.Subjects complaining of hair fall and damage.
- •4.Subjects willing to give a written informed consent and willing to abide by and comply with the study protocol.
- •5.Subjects falling under Grade 3 - Grade 6 of hair lossseverity grade evaluated as per MSCR photo numerical 10-point scale (Linear scale for assessment purpose-In Use Scale)
排除标准
- •1.Subjects who have undergone hair growth treatment within 3 months before screening into the study.
- •2.Subjects having any active scalp disease which may interfere in the study â?? dermatologistâ??s judgement.
- •3.Subjects who have undergone chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study.
- •4.Subjects who have history of alcoholism, smoking, crash dieting and/ or psychiatric disorder including trichotillomania.
- •5.Subjects who have had hair transplant, who have taken pharmaceutical product which cause hirsutism (ex. phenytoin) and finasteride for androgenic alopecia, under medical treatment for hair problems.
- •6. Subjects taking food or vitamin supplements that may compromise the study
- •7.Subjects who wear wig or hair extensions
- •8.Subjects on oral medications, undergoing any chemical hair salon treatment-straightening / perming / color/ henna which will compromise the study.
- •9.Subjects with chronic illness which may influence the study.
- •10.Subjects who are pregnant or lactating or nursing as established with medical history
- •11.Menopausal female subjects as determined by medical history.
- •12.Subjects participating in other similar cosmetic or therapeutic trial within last three months.
- •13.Subjects with any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.
研究者
相似试验
尚未招募
2 期
Effect of Kapikacchu basti in management of Kampavata (Parkinsons disease)CTRI/2017/08/009345Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
进行中（未招募）
不适用
A Phase 3 study of safety and efficacy of Karenitecin versus topotecan administered for 5 consecutive days every 3 weeks in patients with advanced epithelial ovarian canceradvanced epithelial ovarian cancerMedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006950-81-LTBioNumerik Pharmaceuticals, Inc.500
尚未招募
2 期
Phase II Clinical Trial: Efficacy and Safety of Kaempferia Parviflora in Treatment of Chronic Vertigo PatientsDizzinessKaempferia parviflora,chronic vertigo,Dizziness Handicap Inventory,Vestibular functionTCTR20181122001Agricultural Research Development Agency (Public Organization)72
尚未招募
2 期
Efficacy of Karnapooran and Nasya with Eranda Shigruvadi Taila along with Ghritpana in the Management of Karna Badhirya or Sensorineural Hearing Loss.CTRI/2024/06/068457Ayurvedic college Health Department Government of Bihar
已完成
不适用
Efficacy and safety of K-Two® versus Actico® compression system in the management of venous leg ulcers: a pilot studyISRCTN47210331aboratoires Urgo (France)232